Multiple sclerosis other diagnostic studies: Difference between revisions
No edit summary |
No edit summary |
||
Line 12: | Line 12: | ||
==== Antimyelin antibodies ==== | ==== Antimyelin antibodies ==== | ||
[[myelin oligodendrocyte glycoprotein]] ([[Myelin oligodendrocyte glycoprotein|MOG]]) and [[myelin basic protein]] ([[Myelin basic protein|MBP]]) thought to be a predictor of [[disease]] progression but some studies denied any relationship between these auto [[antibodies]] and [[disease]] severity or progression. | [[myelin oligodendrocyte glycoprotein]] ([[Myelin oligodendrocyte glycoprotein|MOG]]) and [[myelin basic protein]] ([[Myelin basic protein|MBP]]) thought to be a predictor of [[disease]] progression but some studies denied any relationship between these auto [[antibodies]] and [[disease]] severity or progression.<ref name="pmid12853586">{{cite journal |vauthors=Berger T, Rubner P, Schautzer F, Egg R, Ulmer H, Mayringer I, Dilitz E, Deisenhammer F, Reindl M |title=Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event |journal=N. Engl. J. Med. |volume=349 |issue=2 |pages=139–45 |date=July 2003 |pmid=12853586 |doi=10.1056/NEJMoa022328 |url=}}</ref><ref name="pmid15623705">{{cite journal |vauthors=Gaertner S, de Graaf KL, Greve B, Weissert R |title=Antibodies against glycosylated native MOG are elevated in patients with multiple sclerosis |journal=Neurology |volume=63 |issue=12 |pages=2381–3 |date=December 2004 |pmid=15623705 |doi= |url=}}</ref><ref name="pmid17251533">{{cite journal |vauthors=Kuhle J, Pohl C, Mehling M, Edan G, Freedman MS, Hartung HP, Polman CH, Miller DH, Montalban X, Barkhof F, Bauer L, Dahms S, Lindberg R, Kappos L, Sandbrink R |title=Lack of association between antimyelin antibodies and progression to multiple sclerosis |journal=N. Engl. J. Med. |volume=356 |issue=4 |pages=371–8 |date=January 2007 |pmid=17251533 |doi=10.1056/NEJMoa063602 |url=}}</ref><ref name="pmid15184621">{{cite journal |vauthors=Lampasona V, Franciotta D, Furlan R, Zanaboni S, Fazio R, Bonifacio E, Comi G, Martino G |title=Similar low frequency of anti-MOG IgG and IgM in MS patients and healthy subjects |journal=Neurology |volume=62 |issue=11 |pages=2092–4 |date=June 2004 |pmid=15184621 |doi= |url=}}</ref> | ||
==References== | ==References== |
Revision as of 13:29, 1 March 2018
Multiple sclerosis Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Multiple sclerosis other diagnostic studies On the Web |
American Roentgen Ray Society Images of Multiple sclerosis other diagnostic studies |
Risk calculators and risk factors for Multiple sclerosis other diagnostic studies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Other Diagnostic Studies
Evoked potential studies
The brain of a person with MS often responds less actively to stimulation of the optic nerve and sensory nerves. These brain responses can be examined using visual evoked potentials (VEPs) and somatosensory evoked potentials (SEPs). Decreased activity on either test can reveal demyelination which may be otherwise asymptomatic. Along with other data, these exams can help find the widespread nerve involvement required for a definite diagnosis of MS.[1]
Antimyelin antibodies
myelin oligodendrocyte glycoprotein (MOG) and myelin basic protein (MBP) thought to be a predictor of disease progression but some studies denied any relationship between these auto antibodies and disease severity or progression.[2][3][4][5]
References
- ↑ Gronseth GS; Ashman EJ. Practice parameter: the usefulness of evoked potentials in identifying clinically silent lesions in patients with suspected multiple sclerosis (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000 May 9;54(9):1720–5. PMID 10802774
- ↑ Berger T, Rubner P, Schautzer F, Egg R, Ulmer H, Mayringer I, Dilitz E, Deisenhammer F, Reindl M (July 2003). "Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event". N. Engl. J. Med. 349 (2): 139–45. doi:10.1056/NEJMoa022328. PMID 12853586.
- ↑ Gaertner S, de Graaf KL, Greve B, Weissert R (December 2004). "Antibodies against glycosylated native MOG are elevated in patients with multiple sclerosis". Neurology. 63 (12): 2381–3. PMID 15623705.
- ↑ Kuhle J, Pohl C, Mehling M, Edan G, Freedman MS, Hartung HP, Polman CH, Miller DH, Montalban X, Barkhof F, Bauer L, Dahms S, Lindberg R, Kappos L, Sandbrink R (January 2007). "Lack of association between antimyelin antibodies and progression to multiple sclerosis". N. Engl. J. Med. 356 (4): 371–8. doi:10.1056/NEJMoa063602. PMID 17251533.
- ↑ Lampasona V, Franciotta D, Furlan R, Zanaboni S, Fazio R, Bonifacio E, Comi G, Martino G (June 2004). "Similar low frequency of anti-MOG IgG and IgM in MS patients and healthy subjects". Neurology. 62 (11): 2092–4. PMID 15184621.